The trial focused on: Percentage of body weight lost Changes in blood sugar levels Shifts in blood pressure Tolerability at different doses, including the highest dose Safety over a longer treatment period This approach helped determine how the Eli Lilly weight-loss study compares to earlier GLP-1 research
Although current evidence is encouraging, further research is needed to confirm long-term outcomes
When you come off the drug, you can continue with diet, exercise, and lifestyle adjustments
For the broader population of healthy adult researchers, GHK-Cus side effect profile makes it one of the more forgiving compounds in the regenerative peptide category
Tirzepatide, with its dual GIP/GLP-1 action, may offer even stronger glycemic benefits, though this remains to be confirmed in a postpartum-specific population